RESEARCH MONOGRAPH · KDC-MN-121

Idebenone

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

65/100

Synthetic ubiquinone analog with one approved indication and a complicated mitochondrial profile

Idebenone is a synthetic short-chain quinone, structurally related to ubiquinone but with a hydroxyl-decyl side chain replacing the longer isoprenoid tail, which gives it different solubility, different membrane behavior, and importantly different electron-transport behavior than native CoQ10. Developed by Takeda in Japan in the 1980s, idebenone has been around long enough that the pharmacology is fairly well-mapped.

The approved-indication story is Leber's hereditary optic neuropathy (LHON), where idebenone marketed as Raxone (Santhera Pharmaceuticals) has European Medicines Agency approval based on the RHODOS trial. The mechanism for LHON is partly bypassing Complex I dysfunction by donating electrons more downstream in the respiratory chain. That's an unusual and informative mechanism: idebenone isn't just a CoQ10 analog, in some contexts it actively differs from CoQ10 in its respiratory chain interactions.

Beyond LHON the picture gets messier. Idebenone has been tested in Friedreich's ataxia (NICOSIA, MICONOS trials) with mixed and largely disappointing results on cardiac and neurological endpoints. The Alzheimer's trials in the 1990s (most prominently the Gutzmann 1998 trial) showed some signals on cognitive endpoints at high doses but couldn't replicate against AChE inhibitors when those became standard of care. Cosmetic dermatology uses idebenone topically as an antioxidant, with the original Prevage formulation having some skin endpoint data.

Mechanistically idebenone can shuttle electrons in a more reduction-state-dependent way than CoQ10, and at high concentrations in some cellular contexts can actually inhibit Complex I (or compete with native ubiquinone) rather than support it. This dual behavior is part of why the clinical results vary so much by context. It's not always a simple "boost mitochondrial function" molecule.

What we like: rigorous orphan-indication approval based on a real RCT, well-characterized small molecule, decent safety profile at clinical doses. The mechanism subtleties make it interesting from a research perspective.

What we dont like is the supplement-market generalization. Idebenone gets sold as a "smart CoQ10" or general nootropic with mitochondrial benefits, when its actual pharmacology is more complex and the cognitive trial base outside LHON is largely negative or mixed.

Sourcing: idebenone synthesis is moderately complex but well-characterized, generic material at HPLC 98%+ purity is available from research-chemical suppliers. Raxone is the pharmaceutical-grade material for clinical use. The molecule is reasonably stable.

Real drug for one specific genetic mitochondrial disorder. Less interesting as a general supplement.

Evidence: 65
Mechanism: 78
Reliability: 55
Safety: 78
Sourcing: 75
Value: 55
Signal: 50
Staying power: 60

Plain-language summary Intrigue 65 / 100

Idebenone is a synthetic CoQ10 analog with better blood-brain barrier penetration. Approved in Europe (Raxone) for Leber hereditary optic neuropathy, a rare mitochondrial eye disease. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Synthetic ubiquinone analog

A short-chain synthetic ubiquinone analog approved in Europe for Leber hereditary optic neuropathy, with reduced lipophilicity and better water solubility than CoQ10.

Abstract

Idebenone (Raxone, Catena, Sovrima; CAS 58186-27-9; molecular formula C19H30O5; molecular weight 338.44) is a synthetic short-chain ubiquinone analog with the 10-carbon isoprenoid tail of CoQ10 replaced by a 10-carbon hydroxyalkyl chain. The structural modification substantially increases water solubility while preserving the redox-cycling quinone chemistry. The compound is approved in Europe (Raxone) for Leber hereditary optic neuropathy, a mitochondrial complex I disease producing acute optic neuropathy. Idebenone bypasses dysfunctional Complex I by directly transferring electrons from cytosolic NADH to Complex III. The compound has also been studied in Alzheimer disease (mixed results, did not advance to FDA approval), Friedreich ataxia (modest effects, no approval), and Duchenne muscular dystrophy. Reported research dose ranges in the literature for LHON are around 900 mg.

Mechanism of action

Synthetic ubiquinone with reduced lipophilicity. Bypasses dysfunctional Complex I in mitochondrial disease.

Reported research dose ranges

Reported research dose ranges in the literature for LHON are around 900 mg.

References

Klopstock T, et al. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain 2011.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-121

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Idebenone

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs